Bacterial contamination of platelet concentrates: Perspectives for the future

Laboratory Medicine

Volumn 41, Issue 5, 2010, Pages 301-305

  Canellini, Giorgia ^a   Waldvogel, Sophie ^a   Anderegg, Karin ^a   Tissot, Jean Daniel ^a  

^a Service Regional Vaudois de Transfusion Sanguine   (Switzerland)

Author keywords

Bacteria; Pathogen detection; Pathogen reduction; Platelets; Transfusion

Indexed keywords

THROMBOCYTE CONCENTRATE;

ACUTE LUNG INJURY; BACTERIAL GROWTH; BACTERIUM DETECTION; BLOOD TRANSFUSION; BLOOD TRANSFUSION REACTION; ERYTHROCYTE; MICROBIAL CONTAMINATION; MORBIDITY; MORTALITY; PATHOGENESIS; REVIEW; SEPSIS; THROMBOCYTE; THROMBOCYTE TRANSFUSION;

BACTERIA (MICROORGANISMS);

EID: 77951963610     PISSN: 00075027     EISSN: None     Source Type: Journal    
DOI: 10.1309/LMQO2P2BSG1XXCSH     Document Type: Review

References (48)

1. Faber JC. Review of the main haemovigilance systems in the world. Transfus Clin Biol. 2009;16:86-92.
2. Michlig C, Vu DH, Wasserfallen JB, et al. Three years of haemovigilance in a general university hospital. Transfus Med. 2003;13:63-72. (Pubitemid 36522967)
3. Andreu G, Morel P, Forestier F, et al. Hemovigilance network in France: Organization and analysis of immediate transfusion incident reports from 1994 to 1998. Transfusion. 2002;42:1356-1364.
4. Allain JP, Stramer SL, Carneiro-Proietti AB, et al. Transfusion- transmitted infectious diseases. Biologicals. 2009;37:71-77.
5. Hillyer CD, Josephson CD, Blajchman MA, et al. Bacterial contamination of blood components: Risks, strategies, and regulation: Joint ASH and AABB educational session in transfusion medicine. Hematology (Am Soc Hematol Educ Program). 2003;575-589.
6. Eder AF, Kennedy JM, Dy BA, et al. Bacterial screening of apheresis platelets and the residual risk of septic transfusion reactions: The American Red Cross experience (2004-2006). Transfusion. 2007;47:1134-1142.
7. Ness P, Braine H, King K, et al. Single-donor platelets reduce the risk of septic platelet transfusion reactions. Transfusion. 2001;41:857-861. (Pubitemid 32642756)
8. Yomtovian RA, Palavecino EL, Dysktra AH, et al. Evolution of surveillance methods for detection of bacterial contamination of platelets in a university hospital, 1991 through 2004. Transfusion. 2006;46:719-730.
9. Walther-Wenke G. Incidence of bacterial transmission and transfusion reactions by blood components. Clin Chem Lab Med. 2008;46:919-925.
10. Blajchman MA, Beckers EA, Dickmeiss E, et al. Bacterial detection of platelets: Current problems and possible resolutions. Transfus Med Rev. 2005;19:259-272. (Pubitemid 41415653)
11. Vamvakas EC, Blajchman MA. Transfusion-related mortality: The ongoing risks of allogeneic blood transfusion and the available strategies for their prevention. Blood. 2009;113:3406-3417.
12. Wagner SJ. Transfusion-transmitted bacterial infection: Risks, sources and interventions. Vox Sang. 2004;86:157-163. (Pubitemid 38529504)
13. Morel P, Deschaseaux M, Bertrand X, et al. Transfusion-transmitted bacterial infection: Residual risk and perspectives of prevention. Transfus Clin Biol. 2003;10:192-200.
14. Yomtovian RA, Palavecino EL, Dysktra AH, et al. Evolution of surveillance methods for detection of bacterial contamination of platelets in a university hospital, 1991 through 2004. Transfusion. 2006;46:719-730.
15. Kuehnert MJ, Roth VR, Haley NR, et al. Transfusion-transmitted bacterial infection in the United States, 1998 through 2000. Transfusion. 2001;41:1493-1499.
16. McDonald CP, Roy A, Mahajan P, et al. Relative values of the interventions of diversion and improved donor-arm disinfection to reduce the bacterial risk from blood transfusion. Vox Sang. 2004;86:178-182. (Pubitemid 38529507)
17. Fournier-Wirth C, Deschaseaux M, Defer C, et al. Evaluation of the enhanced bacterial detection system for screening of contaminated platelets. Transfusion. 2006;46:220-224. (Pubitemid 43381757)
18. Holme S, McAlister MB, Ortolano GA, et al. Enhancement of a culture-based bacterial detection system (eBDS) for platelet products based on measurement of oxygen consumption. Transfusion. 2005;45:984-993. (Pubitemid 40798791)
19. Eder AF, Kennedy JM, Dy BA, et al. Limiting and detecting bacterial contamination of apheresis platelets: Inlet-line diversion and increased culture volume improve component safety. Transfusion. 2009 Apr 28. (Epub ahead of print)
20. Schmidt M, Karakassopoulos A, Burkhart J, et al. Comparison of three bacterial detection methods under routine conditions. Vox Sang. 2007;92:15-21. (Pubitemid 44950345)
21. te Boekhorst PA, Beckers EA, Vos MC, et al. Clinical significance of bacteriologic screening in platelet concentrates. Transfusion. 2005;45:514-519.
22. Solheim BG. Pathogen reduction of blood components. Transfus Apher Sci. 2008;39:75-82.
23. Wollowitz S. Fundamentals of the psoralen-based Helinx technology for inactivation of infectious pathogens and leukocytes in platelets and plasma. Semin Hematol. 2001;38:4-11. (Pubitemid 33096553)
24. Lin L, Dikeman R, Molini B, et al. Photochemical treatment of platelet concentrates with amotosalen and long-wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteria. Transfusion. 2004;44:1496-1504. (Pubitemid 39318986)
25. Lin L, Hanson CV, Alter HJ, et al. Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long-wavelength ultraviolet light. Transfusion. 2005;45:580-590. (Pubitemid 40503810)
26. Naegelen C, Isola H, Dernis D, et al. Evolution of techniques for preparation of labile blood products (LBP): Pathogen inactivation in LBP. Transfus Clin Biol. 2009;16:179-189.
27. Grass JA, Hei DJ, Metchette K, et al. Inactivation of leukocytes in platelet concentrates by photochemical treatment with psoralen plus UVA. Blood. 1998;91:2180-2188. (Pubitemid 28185525)
28. Osselaer JC, Messe N, Hervig T, et al. A prospective observational cohort safety study of 5,106 platelet transfusions with components prepared with photochemical pathogen inactivation treatment. Transfusion. 2008;48:1061-1071. (Pubitemid 351793479)
29. Osselaer JC, Cazenave JP, Lambermont M, et al. An active haemovigilance program characterizing the safety profile of 7,437 platelet transfusions prepared with amotosalen photochemical treatment. Vox Sang. 2008;94:315-323. (Pubitemid 351535733)
30. Rasongles P, Angelini-Tibert MF, Simon P, et al. Transfusion of platelet components prepared with photochemical pathogen inactivation treatment during a Chikungunya virus epidemic in Ile de La Reunion. Transfusion. 2009;49:1083-1091.
31. Apelseth TO, Bruserud O, Wentzel-Larsen T, et al. In vitro evaluation of metabolic changes and residual platelet responsiveness in photochemical treated and gamma-irradiated single-donor platelet concentrates during long-term storage. Transfusion. 2007;47:653-665. (Pubitemid 46449626)
32. McCullough J, Vesole DH, Benjamin RJ, et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: The SPRINT Trial. Blood. 2004;104:1534-1541. (Pubitemid 39166535)
33. Solheim BG, Seghatchian J. The six questions of pathogen reduction technology: An overview of current opinions. Transfus Apher Sci. 2008;39:51-57.
34. Goodrich RP, Edrich RA, Li J, et al. The Mirasol PRT system for pathogen reduction of platelets and plasma: An overview of current status and future trends. Transfus Apher Sci. 2006;35:5-17. (Pubitemid 44354317)
35. Joshi PC. Comparison of the DNA-damaging property of photosensitised riboflavin via singlet oxygen (1O2) and superoxide radical O2- mechanisms. Toxicol Lett. 1985;26:211-217.
36. Perez-Pujol S, Tonda R, Lozano M, et al. Effects of a new pathogen-reduction technology (Mirasol PRT) on functional aspects of platelet concentrates. Transfusion. 2005;45:911-919. (Pubitemid 40798782)
37. Picker SM, Oustianskaia L, Schneider V, et al. Functional characteristics of apheresis-derived platelets treated with ultraviolet light combined with either amotosalen-HCl (S-59) or riboflavin (vitamin B2) for pathogen-reduction. Vox Sang. 2009;97:26-33.
38. Ruane PH, Edrich R, Gampp D, et al. Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion. 2004;44:877-885. (Pubitemid 38738418)
39. Goodrich RP, Gilmour D, Hovenga N, et al. A laboratory comparison of pathogen reduction technology treatment and culture of platelet products for addressing bacterial contamination concerns. Transfusion. 2009;49:1205-1216.
40. Cui Z, Huang Y, Mo Q, et al. Inactivation of lymphocytes in blood products using riboflavin photochemical treatment with visible light. Photochem Photobiol. 2008;84:1195-1200.
41. Reddy HL, Dayan AD, Cavagnaro J, et al. Toxicity testing of a novel riboflavin-based technology for pathogen reduction and white blood cell inactivation. Transfus Med Rev. 2008;22:133-153. (Pubitemid 351384824)
42. Asano H, Lee CY, Fox-Talbot K, et al. Treatment with riboflavin and ultraviolet light prevents alloimmunization to platelet transfusions and cardiac transplants. Transplantation. 2007;84:1174-1182. (Pubitemid 350125361)
43. Jackman RP, Heitman JW, Marschner S, et al. Understanding loss of donor white blood cell immunogenicity after pathogen reduction: Mechanisms of action in ultraviolet illumination and riboflavin treatment. Transfusion. 2009;49:2686-2699.
44. Mohr H, Steil L, Gravemann U, et al. A novel approach to pathogen reduction in platelet concentrates using short-wave ultraviolet light. Transfusion. 2009;49:2612-2629.
45. Mohan KV, Rao SS, Atreya CD. Evaluation of antimicrobial peptides as novel bactericidal agents for room temperature-stored platelets. Transfusion. 2009;50:166-172.
46. Alter HJ. Pathogen reduction: A precautionary principle paradigm. Transfus Med Rev. 2008;22:97-102.
47. Blajchman MA. Protecting the blood supply from emerging pathogens: The role of pathogen inactivation. Transfus Clin Biol. 2009;16:70-74.
48. Blumberg N, Heal JM. Mortality risks, costs, and decision making in transfusion medicine. Am J Clin Pathol. 2000;114:934-937. (Pubitemid 33051894)